Tsveta Milanova - 03 Jan 2023 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role
Chief Commercial Officer
Signature
/s/ William Cook, as Attorney in Fact for Tsveta Milanova
Issuer symbol
AGIO
Transactions as of
03 Jan 2023
Net transactions value
$0
Form type
4
Filing time
05 Jan 2023, 15:11:00 UTC
Next filing
30 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGIO Stock option (right to buy) Award $0 +135,682 $0.000000 135,682 03 Jan 2023 Common stock 135,682 $27.53 Direct F1
transaction AGIO Restricted stock units Award $0 +25,426 $0.000000 25,426 03 Jan 2023 Common stock 25,426 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on January 3, 2023. The shares underlying this option vest as to 25% of the underlying shares on January 3, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F3 The restricted stock units were granted on January 3, 2023. Beginning on January 3, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.